Hypoxic microenvironment and hepatocellular carcinoma treatment

Abstract

Hepatocellular carcinoma (HCC) is one of the most rapidly growing and prevalent cancers in the whole world. The characterized hypoxia region inside the HCC tumors has been recently found as the key driver of HCC malignance and treatment failure, leading to a variety of hypoxia-related biological consequences including angiogenesis, metastasis, metabolism deregulation and drug resistance, which ultimately resulted in treatment failure of HCC. This review will summarize the signaling pathways involved in hypoxia-mediated malignance of HCC and discuss current advances of hypoxia-targeted therapies.

Keywords

Hepatocellular carcinoma / anti-cancer drugs / hypoxia-targeting strategie

References

[1] Marquardt JU.SnapShot: hepatocellular carcinoma.Cancer Cell2014;25:550-1

[2] Wong CC,Ng IO.The impact of hypoxia in hepatocellular carcinoma metastasis.Front Med2014;8:33-41

[3] Beasley RP.Hepatitis B virus. The major etiology of hepatocellular carcinoma..Cancer1988;61:1942-56

[4] Rehermann B.Immunology of hepatitis B virus and hepatitis C virus infection.Nat Rev Immunol2005;5:215-29

[5] Severi T,Verslype C.Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets.Acta Pharmacol Sin2010;31:1409-20 PMCID:PMC4003336

[6] Chen C.Hypoxia inducible factors in hepatocellular carcinoma.Oncotarget2017;8:46691-703

[7] Jain RK.Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science2005;307:58-62

[8] Kasper LH,Boyd K,Biesen M,Baudino TA,Brindle PK.Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression.EMBO J2005;24:3846-58 PMCID:PMC1283945

[9] Chouaib S,Kosmatopoulos K.Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.Oncogene2017;36:439-45 PMCID:PMC5937267

[10] Mizukami Y,Zhang X,Iliopoulos O.Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer.Cancer Res2004;64:1765-72

[11] Choi SB,Song TJ.Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line.Int J Mol Med2011;28:449-54

[12] Ndubuizu OI,Li A.Hypoxia-inducible factor-1 (HIF-1)-independent microvascular angiogenesis in the aged rat brain.Brain Res2010;1366:101-9 PMCID:PMC3378376

[13] Adamski J,Dive C.Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha.PLoS One2013;8:e65304 PMCID:PMC3681794

[14] Wilson WR.Targeting hypoxia in cancer therapy.Nat Rev Cancer2011;11:393-410

[15] Kim KR,Kim KW.Hypoxia-induced angiogenesis in human hepatocellular carcinoma.J Mol Med2002;80:703-14

[16] Hamaguchi T,Tsunedomi R,Miyamoto T,Tokuhisa Y,Takashima M,Oka M.Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma.Int J Oncol2008;33:725-31

[17] Dai XY,Wang DD,Chang LL,Zhu DF,Zhu H.Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.Oncotarget2016;7:6933-47

[18] Xiong XX,Hu DX.Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma.Mol Pharmacol2017;92:246-55

[19] Mahon PC,Semenza GL.FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity.Genes Dev2001;15:2675-86 PMCID:PMC312814

[20] McNeill LA,Claridge TD,Horsfall LE.Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803.Biochem J2002;367:571-5 PMCID:PMC1222951

[21] Semenza GL.Hydroxylation of HIF-1: oxygen sensing at the molecular level.Physiology2004;19:176-82

[22] Liu L,Wang WQ,Qin Y,Sun HC.Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis.Clin Cancer Res2010;16:2740-50

[23] Yan W,Tian D,Liu M,Xia L,Luo M.PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells.Biochem Biophys Res Commun2009;382:631-6

[24] Zhang Q,Chen W,Hu Q,Xie S,Hu L,Liang T.Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling.Carcinogenesis2013;34:962-73

[25] Xu W,Cheng M,Liu Z,Luo X,Chen T,Xiao J.Hypoxia activates Wnt/beta-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma.Sci Rep2017;7:40446 PMCID:PMC5225427

[26] Jiao M.Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.Int J Oncol2012;40:461-8

[27] Fu J,Cao J,Qian YW,Ren YB,Cao GW,Yan YQ,Wu MC,Wang HY.p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways.Hepatology2011;53:181-92

[28] Zhang L,Li X,Jiang Y,Liu J,Zhu J,Dong J.Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1alpha in hepatocellular carcinoma.BMC Cancer2013;13:108 PMCID:PMC3614870

[29] Zhu AX,Sahani DV.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol2011;8:292-301 PMCID:PMC3266719

[30] Forsythe JA,Iyer NV,Leung SW,Semenza GL.Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.Mol Cell Biol1996;16:4604-13 PMCID:PMC231459

[31] Ju C,Eltzschig HK.Hypoxia-inducible factors as molecular targets for liver diseases.J Mol Med (Berl)2016;94:613-27 PMCID:PMC4879168

[32] Josko J,Jedrzejowska-Szypulka H.Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.Med Sci Monit2000;6:1047-52

[33] Maegdefrau U,Winklmeier A,Schubert T,Schardt K,Hellerbrand C.Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.J Pathol2009;218:520-9

[34] Wang X,Jia L,Lang M,Lan C,Hao J,Qin T,Yang S,Ren H.HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma.Cancer Lett2017;393:113-24

[35] Semenza GL.Targeting HIF-1 for cancer therapy.Nat Rev Cancer2003;3:721-32

[36] Okazaki I.Novel strategies for hepatocellular carcinoma based on MMPs science.Anticancer Agents Med Chem2012;12:753-63

[37] Yamada N,Ohyama H,Nakasho K,Okamura H.Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1alpha-dependent manner.Int J Oncol2012;41:2005-12

[38] Clambey ET,Westrich JA,Campbell EL,de Zoeten EF,Stenmark KR,Eltzschig HK.Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa.Proc Natl Acad Sci U S A2012;109:E2784-93 PMCID:PMC3478644

[39] Liu Y,Tohme S,Fu Y,Lotze M,Tsung A.Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9.J Hepatol2015;63:114-21 PMCID:PMC4475488

[40] Yan W,Liang X,Huang H,Monga SP,Lotze MT.High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.Hepatology2012;55:1863-75 PMCID:PMC4610360

[41] Valero V3rd,Anders RA.Emerging role of Hpo signaling and YAP in hepatocellular carcinoma.J Hepatocell Carcinoma2015;2:69-78 PMCID:PMC4918286

[42] Zhao B,Lei Q.The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version.Genes Dev2010;24:862-74 PMCID:PMC2861185

[43] Zhou TY,Hu Y,Lin WK,Wan ZQ,Chen Y,Chen ZB,Lou JS,Zhu H.Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.Sci Rep2016;6:30483 PMCID:PMC4967870

[44] Chen R,Fan XG,Lotze MT,Billiar TR,Tang D.High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.Hepatology2018;67:1823-41

[45] Llovet JM,Mazzaferro V,Gane E,de Oliveira AC,Raoul JL,Schwartz M,Zeuzem S,Greten TF,Seitz JF,Häussinger D,Shan M,Voliotis D,SHARP Investigators Study Group..Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[46] Moen I.Hyperbaric oxygen therapy and cancer--a review.Target Oncol2012;7:233-42 PMCID:PMC3510426

[47] Cheng X,Cheng W,Ma C,Hua ZC.Tumor-specific delivery of histidine-rich glycoprotein suppresses tumor growth and metastasis by anti-angiogenesis and vessel normalization.Curr Gene Ther2014;14:75-85

[48] Guise CP,Ashoorzadeh A,Lin WH,Smaill JB,Ding K.Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Chin J Cancer2014;33:80-6 PMCID:PMC3935009

[49] Limani P,Kron P,Pestalozzi B,Jetter A,Mullhaupt B,Nicolau C,Petrowsky H,Graf R.Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - protocol of a first Ib/IIa clinical trial.BMC Cancer2016;16:812 PMCID:PMC5070093

[50] Rischin D,Oza AM,Bernshaw D,Hicks R,Fyles A.Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer.Int J Gynecol Cancer2010;20:827-33

[51] Emmenegger U,Francia G,Franco M,Man S.Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.Cancer Res2006;66:1664-74

[52] Reck M,Nimmermann C,Gatzemeier U.Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC).Pneumologie2004;58:845-9

[53] Johnson CA,von Roemeling R,Graham MA,Kennedy G,O'Dwyer PJ.Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.J Clin Oncol1997;15:773-80

[54] Cai TY,Zhu H,Zhang J,Lou JS,Yang B.Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1alpha.Mol Cancer Ther2014;13:630-42

[55] Liu XW,Zhu H,Su Y,He QJ.Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma.Autophagy2014;10:111-22 PMCID:PMC4389865

[56] Chang L,Wang D,Zhou T,Sheng R,Du Y,Yang B.Hypoxia-targeted drug Q6 induces G2-M arrest and apoptosis via poisoning topoisomerase II under hypoxia.PLoS One2015;10:e0144506 PMCID:PMC4674137

[57] Selvendiran K,Vishwanath S,Trigg NJ,Hideg K.EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.J Biol Chem2007;282:28609-18 PMCID:PMC4610350

[58] Zhao R,Zhang Y,Jin Y,Zhang F.EF24 suppresses invasion and migration of hepatocellular carcinoma cells in vitro via inhibiting the phosphorylation of Src.Biomed Res Int2016;2016:8569684 PMCID:PMC5141541

[59] Jeong W,Park SR,Chen A,Turkbey B,Choyke P,Kummar S.Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid tumors.Cancer Chemother Pharmacol2014;73:343-8

[60] Moser C,Mori A,Schlitt HJ,Fogler WE.ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo.BMC Cancer2008;8:206 PMCID:PMC2496914

[61] Granowitz EV,Benson RM,Band V,Osborne BA.Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation.Anticancer Res2005;25:3833-42